Outcomes4Me Inc., the developer of the leading, direct-to-patient, AI-driven platform transforming the cancer-care experience, announced today that its German affiliate Outcomes4Me Germany GmbH has acquired the assets associated with the Mika Health app from Berlin-based Fosanis GmbH. The Mika app has served over 100,000 cancer patients globally, and is a clinically validated platform proven in clinical trials to reduce a range of symptoms associated with cancer care including depression, anxiety, and fatigue.
Outcomes4Me, which supports more than 280,000 cancer patients, recently finalized a $21M funding round, emphasizing the company’s plans to expand both its patient community and commercial business globally. This acquisition strengthens Outcomes4Me’s platform with Mika’s proven interventions for real-time symptom management, behavioral coaching, and emotional support, setting a new global standard for digital oncology support. It also allows Outcomes4Me to scale faster in European markets, leveraging Mika’s regulatory readiness as MDR IIa-certified medical device and local partnerships.
“With this acquisition, we’re taking a major step toward our mission to make cancer understandable and manageable to every patient wherever and whomever they are,” said Maya R.Said, Sc.D., Founder and CEO of Outcomes4Me. “Mika’s proven AI-driven emotional support technology and European footprint complement our evidence-based platform grounded in clinical guidelines and U.S. footprint. Together, we’re building the most comprehensive digital companion for cancer patients worldwide.”
“Joining forces with Outcomes4Me allows us to take our vision further, faster,” said Gandolf Finke, Ph.D., Founder and Managing Director of Fosanis GmbH. “We’re excited to integrate our technology with a partner that shares our values of transparency, trust, and patient empowerment. The overlap in our customer base of global pharmaceutical companies that prioritize innovation and whole-patient care creates many synergies and allows us to immediately deliver combined value for our patients and business partners alike. For our patients using Mika, this transaction has no impact in terms of service they can expect.”
